In 2025, the iCAN Laboratory maintained its strategic focus on developing "microenvironment-immune modulatory nanocarrier systems", achieving significant advancements in lipid-based nanobiomaterials and therapeutic applications for autoimmune diseases. This work has contributed novel insights and methodologies to the field of immunotherapy.
The laboratory's research efforts centered on designing precision-targeted lipid nanocarrier systems and hydrogel-based delivery platforms, capable of selectively addressing diverse physiological and pathological microenvironments. Key targets included tumor microenvironments, lymph node mechanical niches, and autoimmune disease-associated microenvironments. These efforts established a robust framework for context-specific immune modulation, enabling tailored therapeutic interventions. Future investigations will further explore strategies to balance immune enhancement and immune tolerance, expanding the therapeutic scope of immune regulation. Looking ahead to 2026, the iCAN Laboratory remains committed to translating foundational research discoveries into clinically actionable solutions. By bridging cutting-edge nanotechnology with translational medicine, the lab aims to address unmet clinical needs and advance global biomedical innovation.
Acknowledgments
The laboratory extends its sincere gratitude to Professor Liang Xingjie and his team at the National Center for Nanoscience and Technology for their invaluable academic guidance and collaborative expertise. We also acknowledge the School of Biomedical Engineering at Guangzhou Medical University for providing state-of-the-art research facilities and resources. Financial support from the National Natural Science Foundation of China is deeply appreciated. These collaborations and resources have been indispensable to the lab's sustained progress and impact.
